Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: Study based on experience at the Hospital Universitario Central de Asturias

Clinical and Translational Oncology

Volumn 12, Issue 8, 2010, Pages 562-567

  Muriel, Carolina ^a   Esteban, Emilio ^a   Corral, Norberto ^b   Fonseca, Paula J ^a   Luque, María ^a   Berros, José Pablo ^a   Fernández, Yolanda ^a   Blay, Pilar ^a   Fra, Joaquín ^a   Villanueva, Noemí ^a   Sanmamed, Miguel ^a   Pardo, Pablo ^a   Izquierdo, Marta ^a   Vieitez, José María ^a   Estrada, Enrique ^a   Lacave, Ángel J ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Advanced renal cell carcinoma; Cytokines; Efficacy; Toxicity; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOKINE; HEMOGLOBIN; INTERLEUKIN 2; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RESPIRATORY TRACT INFLAMMATION; RETROSPECTIVE STUDY; SKIN TOXICITY; SPAIN; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77958198444     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0554-0     Document Type: Article

References (34)

1. P.A. Godley K.I. Ataga 2000 Renal cell carcinoma Curr Opin Oncol 12 260 264 1:STN:280:DC%2BD3cvisVOitw%3D%3D 10.1097/00001622-200005000-00013 10841199 (Pubitemid 32043606)
2. American Cancer Society (2004) Cancer facts and figures 2004. http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2004
3. J.J. Patard E. Leray N. Rioux-Leclercq, et al. 2005 Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience J Clin Oncol 23 2763 2771 10.1200/JCO.2005.07.055 15837991 (Pubitemid 46179466)
4. A. Jemal T. Murray E. Ward, et al. 2005 Cancer statistics, 2005 Cancer J Clin 55 10 30 10.3322/canjclin.55.1.10 (Pubitemid 40310185)
5. P. Vineis M. Alavanja P. Buffer, et al. 2004 Tobacco and cancer: recent epidemiological evidence J Natl Cancer Inst 96 99 106 1:STN:280: DC%2BD2c%2FjsV2rsw%3D%3D 10.1093/jnci/djh014 14734699 (Pubitemid 38195900)
6. E.E. Calle R. Kaaks 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nat Rev Cancer 4 579 591 1:CAS:528: DC%2BD2cXmtVOhsLk%3D 10.1038/nrc1408 15286738 (Pubitemid 39025053)
7. M. Gago-Dominguez J.M. Yuan J.E. Castelao, et al. 1999 Regular use of analgesics is risk factor for renal cell carcinoma Br J Cancer 81 542 548 1:STN:280:DyaK1MvjsFKnsg%3D%3D 10.1038/sj.bjc.6690728 10507783 (Pubitemid 29458812)
8. S. Satoh N. Tsuchiya T. Habuchi, et al. 2005 Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis J Urol 174 1749 1753 10.1097/01.ju.0000177489.98031.54 16217276 (Pubitemid 41546926)
9. R.J. Motzer J. Bacik B.A. Murphy, et al. 2002 Interferon-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289 296 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D 10.1200/JCO.20.1.289 11773181 (Pubitemid 34032623)
10. R.C. Flanigan S.E. Salmon B.A. Blumenstein, et al. 2001 Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655 1659 1:CAS:528: DC%2BD3MXovFKjt74%3D 10.1056/NEJMoa003013 11759643 (Pubitemid 33126820)
11. G.H. Mickisch A. Garin H. van Poppel, et al. 2001 Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966 970 1:CAS:528:DC%2BD3MXntF2qtbw%3D 10.1016/S0140-6736(01)06103-7 11583750 (Pubitemid 32913522)
12. C.F. Rochlitz H. Lobeck S. Peter, et al. 1992 Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype Cancer 69 2993 2998 1:STN:280:DyaK383nsVehsw%3D%3D 10.1002/1097- 0142(19920615)69:12<2993::AID-CNCR2820691222>3.0.CO;2-V 1350506
13. J.R. Gnarra K. Tory Y. Weng, et al. 1994 Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 85 90 1:CAS:528: DyaK2cXktlaitbg%3D 10.1038/ng0594-85 7915601 (Pubitemid 24232386)
14. O. Iliopoulos A.P. Levy C. Jiang, et al. 1996 Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc Natl Acad Sci USA 93 10595 10599 1:CAS:528:DyaK28XmtVOlsb4%3D 10.1073/pnas.93.20.10595 8855223 (Pubitemid 26333032)
15. P.H. Maxwell M.S. Wiesener G.W. Chang, et al. 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 271 275 1:CAS:528:DyaK1MXjsFyqt74%3D 10.1038/20459 10353251 (Pubitemid 29246458)
16. X. Na G. Wu C.K. Ryan, et al. 2003 Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas J Urol 170 588 592 1:CAS:528:DC%2BD3sXlsVKgur4%3D 10.1097/01.ju.0000074870.54671.98 12853836 (Pubitemid 36870265)
17. R.J. Motzer T.E. Hutson P. Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
18. B.J. Escudier J. Bellmunt S. Negrier, et al. 2009 Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) J Clin Oncol 27 [Suppl] 15s
19. B.I. Rini S. Halabi J. Rosenberg, et al. 2009 Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 J Clin Oncol 27 [Suppl] 18s
20. B. Escudier C. Szezylik T. Eisen, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 1:CAS:528: DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
21. R.J. Motzer T.E. Hutson P. Tomczak, et al. 2009 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584 3590 1:CAS:528: DC%2BD1MXhtVOnu7nI 10.1200/JCO.2008.20.1293 19487381
22. G. Hudes M. Carducci P. Tomczak, et al. 2007 A Phase III, three-arm, randomized, open-label study of interferon alfa alone, CCI-779 alone and the combination of interferon alfa and CCI-779 in fist-line poor-prognosis subjects with advanced renal cell carcinoma N Engl J Med 356 2271 2281 1:CAS:528:DC%2BD2sXmtVKkurs%3D 10.1056/NEJMoa066838 17538086 (Pubitemid 46849157)
23. J. Bellmunt J.L. González-Larriba M.A. Climent, et al. 2007 Sorafenib TARGET trial results in Spanish patients Clin Transl Oncol 9 671 673 1:CAS:528:DC%2BD1cXlslagtg%3D%3D 10.1007/s12094-007-0120-6 17974528
24. R.J. Motzer M. Mazumdar J. Bacik, et al. 1999 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 2530 2540 1:STN:280:DC%2BD3c%2FjtVSnug%3D%3D 10561319 (Pubitemid 29368255)
25. A.B. Miller B. Hooqstraten M. Staquet, et al. 1981 Reporting results of cancer treatment Cancer 47 207 214 1:STN:280:DyaL3M7htFOltw%3D%3D 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 7459811 (Pubitemid 11167383)
26. E.L. Kaplan P. Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
27. E. Esteban J. Carballido V. Navas, et al. 2007 Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 Anticancer Drugs 18 291 296 10.1097/CAD. 0b013e328011a4fc (Pubitemid 46192982)
28. D. Loppow E. Huland H. Heinzer, et al. 2007 Interleukin-2 inhalation therapy temporanly induces asthma-like airway inflammation Eur J Med Res 12 556 562 1:CAS:528:DC%2BD2sXhsVGitr%2FL 18024264 (Pubitemid 350104059)
29. M.J. Ratain T. Eisen W.M. Stadler, et al. 2006 Phase II, placebo-controlled, randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 1:CAS:528:DC%2BD28XmtVOmtrk%3D 10.1200/JCO.2005.03.6723 16636341 (Pubitemid 46630627)
30. R.J. Motzer M.D. Michaelson B.G. Redman, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateled-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D 10.1200/JCO.2005.02.2574 16330672 (Pubitemid 46630489)
31. H.K. Jensen M. Nordsmark F. Donskov, et al. 2008 Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma BJU Int 101 Suppl4 41 44 1:CAS:528:DC%2BD1cXnsVKqs7w%3D 10.1111/j.1464-410X.2008.07649.x 18430123
32. S. Signoretti M. Regan M. Atkins 2008 Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy BJU Int 101 Suppl4 31 35 1:CAS:528:DC%2BD1cXnsVKqs74%3D 10.1111/j.1464-410X.2008.07646.x 18430120
33. A. Ravaud J. Gardner R. Hawkins, et al. 2006 Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma. 2006 ASCO Annual Meeting Proceedings J Clin Oncol 24 18S 4502
34. J.C. Yang L. Haworth R.M. Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 1:CAS:528:DC%2BD3sXms1Klu7w%3D 10.1056/NEJMoa021491 12890841 (Pubitemid 36910021)